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BRIEF REPORT
Secukinumab Provides Significant and Sustained Inhibition of Joint Structural
Damage in a Phase III Study of Active Psoriatic Arthritis
Desiree van der Heijde,1 Robert B. Landewe,2 Philip J. Mease,3 Iain B. McInnes,4 Philip G. Conaghan,5
Luminita Pricop,6 Greg Ligozio,6 Hanno B. Richards,7 and Shephard Mpofu7
Objective. To assess whether secukinumab treat-
ment in patients with active psoriatic arthritis (PsA) is asso-
ciated with sustained inhibition of radiographic progression.
Methods. In this phase III, double-blind, placebo-
controlled study, 606 patients with PsA were randomized to
receive intravenous (IV) secukinumab at a dose of 10 mg/kg
(weeks 0, 2, 4) followed by subcutaneous secukinumab at a
dose of 150 mg or 75 mg (the IVﬁ150 mg and IVﬁ75 mg
groups, respectively) or placebo. Patients were stratified ac-
cording to prior anti–tumor necrosis factor (anti-TNF) expo-
sure (71% were anti-TNF naive). At week 16, placebo-treated
patients who had at least a 20% reduction in the tender and
swollen joint counts (responders) continued to receive pla-
cebo until week 24; nonresponders were re-randomized to
receive secukinumab at a dose of 150 mg or 75mg. The mod-
ified total Sharp/van der Heijde score (SHS) was determined
at baseline, week 16 or 24, and week 52.
Results. In the overall population, radiographic
progression was inhibited through 52 weeks; efficacy was
demonstrated for both erosion and joint space narrow-
ing scores and in patients who switched from placebo to
secukinumab at week 24. Subgroup analyses showed
that secukinumab reduced radiographic progression at
week 24, regardless of previous anti-TNF treatment.
Among anti-TNF–naive patients, the mean changes from
baseline to week 24 in the modified total SHS were 0.05
in the pooled secukinumab group and 0.57 in the placebo
group; among patients with an inadequate response or
intolerance to anti-TNF treatment, the mean changes
were 0.16 and 0.58, respectively. Anti-TNF–naive patients
showed negligible progression through week 52. Inhibi-
tion of structural damage was observed through week 52
irrespective of concomitant methotrexate use. A high pro-
portion of patients receiving secukinumab showed no pro-
gression (change in SHS of£ 0.5) from baseline to week 24
(82.3% of the IVﬁ150 mg group and 92.3% of the
IVﬁ75 mg group) and from week 24 to week 52 (85.7% of
the IVﬁ150mg group and 85.8% of the IVﬁ75mg group).
Conclusion. Secukinumab inhibited radiographic
progression over 52 weeks of treatment in patients with
active PsA.
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Psoriatic arthritis (PsA), a chronic inflammatory
arthritis characterized by structural damage to the joints,
has been associated with reduced health-related quality
of life, disability, and reduced life expectancy (1–3). The
joint changes in PsA are characterized radiographically
by a combination of erosive and proliferative bone changes,
including erosive joint destruction, fluffy periostitis, and
pencil-in-cup deformities (4). Radiographic assessment
of joints is recommended to aid in the diagnosis of PsA,
provide information on disease severity, and assess the
effect of treatment on disease progression (5).
Interleukin-17A (IL-17A) has been implicated in
the pathogenesis of PsA, including progression of joint
damage (6). Cells producing IL-17A are observed in the
joints of patients with PsA and correlate with disease
activity, structural damage, and disease progression (6).
To this end, drugs targeting IL-17A are of interest in the
search for new PsA treatments, and a number of these
agents are currently in late-stage clinical development.
Secukinumab is a fully human IgG1 monoclonal
antibody that selectively binds to and neutralizes IL-
17A. In the placebo-controlled, double-blind, phase III
FUTURE 1 study, secukinumab provided rapid, signifi-
cant, and sustained improvements in key clinical
domains of PsA, including signs and symptoms, physical
functioning, and quality of life (7). Moreover, secukinu-
mab significantly reduced radiographic progression, as
measured by change from baseline to week 24 in the
modified total Sharp/van der Heijde score (SHS) for
PsA (8), compared with placebo (7). The current report
describes 52-week radiography results from FUTURE 1,
and presents the results of analyses related to previous
anti–tumor necrosis factor (anti-TNF) therapy with con-
comitant methotrexate (MTX).
PATIENTS AND METHODS
Details of the FUTURE 1 study (ClinicalTrials.gov
identifier: NCT01392326) design, patient eligibility criteria,
and end points have been previously reported (7). Briefly,
patients with PsA were randomized 1:1:1 to receive secukinu-
mab (10 mg/kg intravenously [IV] at baseline and at weeks 2
and 4 followed by 150 mg [IV!150 mg group] or 75 mg
[IV!75 mg group] administered subcutaneously [SC] every 4
weeks thereafter) or placebo (according to the same sched-
Figure 1. Patient disposition and flow through the trial from screening to week 52. At week 16, patients in the placebo group were classified as non-
responders or responders. Nonresponders were randomized to receive secukinumab 75 mg or 150 mg subcutaneously (SC) at week 16 and then every
4 weeks thereafter. Responders were randomized to receive secukinumab 75 mg or 150 mg SC at week 24 and then every 4 weeks thereafter. Patients
who had radiographic assessments at baseline, week 16 or 24, and week 52 were defined as radiography (x-ray) completers. IV5 intravenous.
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ules). Randomization of the patients was stratified according
to previous exposure to anti-TNF therapy. A washout period of
4–10 weeks after anti-TNF treatment was required prior to ran-
domization. Concomitant MTX therapy was permitted. The
study was approved by the institutional review board or ethics
committees at participating sites and was conducted in accor-
dance with the principles of the Declaration of Helsinki. All
participants provided written informed consent.
At week 16, all patients were assessed for joint-related
responses (tender and swollen joint counts) and were classified
as responders ($20% improvement from baseline in tender
and swollen joint counts) or nonresponders. Placebo-treated
patients were re-randomized (1:1) to receive secukinumab
75 mg or 150 mg SC every 4 weeks without a loading dose
beginning at either week 16 (nonresponders) or week 24
(responders). Nonresponders in the secukinumab treatment
groups continued to receive their assigned treatment. Radio-
graphic progression was measured using the modified total
SHS for PsA, which is the sum of erosion and joint space nar-
rowing (JSN) scores (8). The total possible erosion and JSN
scores are 320 and 208, respectively, resulting in a maximum
modified total SHS of 528. Radiographs of the hands/wrists
and feet were obtained at baseline, week 16 (nonresponders)
or week 24 (responders), and week 52. Radiographs were read
independently by 2 readers (Dr. Charles Peterfy and Dr. Yan
Chen, Spire Sciences, Boca Raton, FL), who were blinded with
regard to radiograph chronology, type of therapy, and patient
clinical status. The mean score was used for all analyses.
A nonparametric analysis of covariance model with
treatment regimen and TNF inhibitor status as factors, and
weight and baseline modified total SHS as covariates was used
to evaluate the effect of secukinumab versus placebo at week
24. Prespecified analysis of stratified subgroups based on previ-
ous anti-TNF therapy was also performed. A subgroup analysis
according to baseline MTX treatment (none versus concomi-
tant) was performed post hoc. For placebo-treated patients
who met the criteria for early escape at week 16 and patients
who discontinued the study prior to week 24, linear extrapola-
tion was used to impute values at week 24. Data for week 52
are presented for radiography completers (defined as patients
who had radiographic assessments at baseline, week 16 or 24,
and week 52), with no extrapolation for missing data. A pre-
planned sensitivity analysis was undertaken to evaluate wheth-
er radiography completer data and linearly extrapolated data
were comparable.
Cumulative probability plots were generated to show
the modified total SHS, erosion score, and JSN score for all
patients according to dose group from baseline to week 24 and
from week 24 to week 52. As recommended in published guide-
lines, a change of #0.5 in the modified total SHS was used to
define no structural progression, and this was assessed from
baseline to week 24 and from week 24 to week 52 in radiogra-
phy completers (9). An exploratory exposure-response analysis
of change in the modified total SHS from week 24 to week 52
versus the trough secukinumab concentration (Cmin) at week
52 was also performed.
RESULTS
Patient disposition and baseline characteristics. A
total of 606 patients were randomized (Figure 1). Demo-
graphics, disease characteristics, prior anti-TNF treat-
ment, and concomitant MTX treatment were comparable
across the groups. Overall, 71% of patients were anti-
TNF naive, and 61% were receiving concomitant MTX
(see Supplementary Table 1, available on the Arthritis &
Rheumatology web site at http://onlinelibrary.wiley.com/
doi/10.1002/art.39685/abstract). The numbers of patients
who had linear extrapolation applied at week 24 were as
follows: 55 in the IV!150 mg group, 40 in the IV!75 mg
group, and 109 in the placebo group.
Radiographic progression at week 24. Secukinu-
mab-treated patients showed significantly less radiogra-
phic progression from baseline to week 24 compared
with placebo-treated patients (Table 1 and Figure 2).
The mean changes in the modified total SHS from base-
line to week 24 were 0.08 in the pooled secukinumab
group, 0.13 in the IV!150 mg group, and 0.02 in the
IV!75 mg group, compared with 0.57 in the placebo
group (all P, 0.05 versus placebo). In the pooled sec-
ukinumab group and the placebo group, the mean chang-
es in the erosion score were 0.06 and 0.35, respectively,
and the mean changes in the JSN score were 0.02 and
0.23, respectively. Radiographic progression was visual-
ized using cumulative probability plots showing change
from baseline to week 24 in the modified total SHS, the
erosion score, and the JSN score. More placebo-treated
patients showed progression (and to a greater extent) than
secukinumab-treated patients (Figure 2 and Supplementa-
ry Figure 1, available on the Arthritis & Rheumatology web
site at http://onlinelibrary.wiley.com/doi/10.1002/art.39685/
abstract).
The impact of applying linear extrapolation for
missing values was evaluated in a sensitivity analysis,
which considered an alternative, last observation car-
ried forward (LOCF) approach for the patients who
were nonresponders at week 16. The mean changes
from baseline to week 24 using LOCF were 0.10 (secu-
kinumab IV!150 mg; P5 0.0253), 0.03 (secukinumab
IV! 75 mg; P5 0.0314), and 0.46 (placebo). For the
active secukinumab arms, using the LOCF approach
produced results comparable with those obtained using
linear extrapolation (mean changes of 0.13 in the IV!
150 mg group and 0.02 in the IV!75 mg group); how-
ever, the value for the placebo arm was greater when
the latter approach was used (mean change 0.57).
Nevertheless, both approaches conclusively demon-
strated that secukinumab treatment inhibited structural
progression.
A separate sensitivity analysis, in which patients
with a mean change in the modified total SHS of .10
were excluded (2 from the placebo group and 1 from
the secukinumab IV!75 mg group), supported the
T1, F2
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robustness of these data. Removal of these 3 outliers
decreased the mean change in the placebo and secukinu-
mab IV!75 mg groups but had little effect on the level
of statistical significance versus placebo (see Supplemen-
tary Table 2, available on the Arthritis & Rheumatology
web site at http://onlinelibrary.wiley.com/doi/10.1002/art.
39685/abstract).
A prespecified analysis of patients stratified acc-
ording to anti-TNF therapy showed less progression in
secukinumab-treated patients compared with placebo-
treated patients among both anti-TNF–naive patients
and patients who had an inadequate response or intoler-
ance to anti-TNF therapy. The mean changes from base-
line to week 24 in the modified total SHS among anti-
TNF–naive patients in the pooled secukinumab,
IV!150 mg, IV!75 mg, and placebo groups were 0.05,
0.15, 20.06, and 0.57, respectively (Table 1). The mean
changes from baseline to week 24 in the modified total
SHS among patients with an inadequate response to
anti-TNF in the pooled secukinumab, IV!150 mg,
IV!75 mg, and placebo groups were 0.16, 0.10, 0.21,
and 0.58, respectively. In an exploratory post hoc analy-
sis, inhibition of structural damage was also observed
irrespective of concomitant MTX therapy (Table 1).
Radiographic assessment at week 52. The
mean changes in the modified total SHS from week 24 to
week 52 among patients initially randomized to receive
secukinumab 150 mg and 75 mg were 0.23 and 0.20,
respectively, compared with mean changes of 0.13 and
0.02, respectively, from baseline to week 24 (Table 1).
From week 24 to week 52, the mean changes in the ero-
sion score in the secukinumab 150 mg and 75 mg groups
were 0.18 and 0.12, respectively, and the mean changes
in the JSN score in the secukinumab 150 mg and 75 mg
Table 1. Changes in the modified total SHS, erosion score, and JSN score from baseline to week 24 (full analysis set) and from week 24 to
week 52 (radiography completers)*
Baseline to week 24 Week 24 to week 52
Population
Secukinumab
IV!150 mg
Secukinumab
IV!75 mg
Secukinumab
pooled Placebo
Secukinumab
150 mg
Secukinumab
75 mg
Secukinumab
pooled
Placebo!
secukinumab
Overall†
No. of patients 185 181‡ 366§ 179 175 169 344 152
Modified SHS 0.136 1.18¶ 0.026 1.60¶ 0.086 1.40¶ 0.576 2.48 0.236 2.41 0.206 1.00 0.216 1.86 20.036 1.62
Erosion score 0.046 0.60# 0.086 0.93# 0.066 0.78# 0.356 1.62 0.186 1.41 0.126 0.71 0.156 1.12 0.016 0.99
JSN score 0.106 0.96 20.066 0.93# 0.026 0.95 0.236 1.24 0.056 1.19 0.086 0.59 0.066 0.94 20.036 0.91
Anti-TNF naive**
No. of patients 135 128 263 129 130 121 251 116
Modified SHS 0.156 1.09 20.066 1.61# 0.056 1.37# 0.576 2.78 20.016 0.81 0.146 0.75 0.066 0.78 20.126 1.70
Erosion score 0.026 0.53 0.006 0.78 0.016 0.66 0.296 1.80 0.066 0.66 0.096 0.43 0.086 0.56 20.026 1.06
JSN score 0.136 1.01 20.066 0.96# 0.046 0.99 0.286 1.37 20.076 0.57 0.056 0.43 20.016 0.51 20.106 0.95
Anti-TNF IR**
No. of patients 50 53 103 50 45 48 93 36
Modified SHS 0.106 1.39# 0.216 1.57 0.166 1.48# 0.586 1.45 0.916 4.53 0.346 1.46 0.616 3.31 0.276 1.29
Erosion score 0.086 0.77# 0.256 1.19 0.176 1.01 0.506 1.02 0.516 2.53 0.206 1.15 0.356 1.94 0.096 0.70
JSN score 0.026 0.82 20.056 0.87 20.016 0.84 0.096 0.79 0.396 2.12 0.136 0.87 0.266 1.59 0.196 0.76
Without concomitant
MTX††
No. of patients 74 76 150 65 69 69 138 54
Modified SHS 0.126 0.78 0.146 1.21 0.136 1.02 0.586 3.24 0.046 0.95 0.166 1.13 0.106 1.04 0.256 1.43
Erosion score 0.026 0.38 0.176 0.90 0.106 0.70 0.376 2.30 0.086 0.55 0.136 0.97 0.106 0.78 0.196 0.96
JSN score 0.106 0.67 20.036 0.70 0.046 0.68 0.216 1.05 20.046 0.65 0.036 0.50 20.016 0.58 0.066 0.73
Concomitant MTX††
No. of patients 111 105 216 114 106 100 206 98
Modified SHS 0.146 1.38 20.076 1.83# 0.046 1.61# 0.576 1.93 0.356 3.00 0.226 0.91 0.296 2.24 20.186 1.70
Erosion score 0.046 0.71# 0.016 0.94# 0.036 0.83# 0.346 1.07 0.256 1.75 0.116 0.46 0.186 1.30 20.096 0.99
JSN score 0.106 1.11 20.086 1.07 0.016 1.10 0.246 1.33 0.106 1.44 0.116 0.64 0.116 1.12 20.096 1.00
* Linear extrapolation was performed at week 24; no linear extrapolation was applied at week 52. Values are the mean6 SD. SHS5 Sharp/van der Heidje
score; JSN 5 joint space narrowing; IV 5 intravenous; anti-TNF IR 5 inadequate response or intolerance to anti–tumor necrosis factor; MTX 5
methotrexate.
† Included in the predefined hierarchical hypothesis testing strategy to adjust for multiplicity at week 24.
‡ The erosion score was determined in 182 patients.
§ The erosion score was determined in 367 patients.
¶ P, 0.05 versus placebo, adjusted for multiplicity of testing.
# P, 0.05 versus placebo, unadjusted.
** Prespecified subgroup analysis.
†† Post hoc subgroup analysis.
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groups were 0.05 and 0.08, respectively. Inhibition of
structural progression was also demonstrated in placebo-
treated patients who switched to secukinumab (Table 1).
The mean change in the modified total SHS from
week 24 to week 52 in placebo-treated patients who
switched to secukinumab was 20.03, compared with 0.57
in patients who received placebo from baseline to week
24. Cumulative probability plots indicated that both secu-
kinumab doses were effective for inhibiting structural
progression through 52 weeks of therapy (Figure 2 and
Supplementary Figure 1, available on the Arthritis &
Rheumatology web site at http://onlinelibrary.wiley.com/
doi/10.1002/art.39685/abstract).
To investigate the effect of using radiography
completer data, a preplanned sensitivity analysis was
conducted using linear extrapolation for patients who
were missing week 52 data but had a postbaseline assess-
ment at week 16 or week 24. The mean changes in the
modified total SHS from baseline to week 52 using linear
extrapolation and radiography completer data were 0.37
and 0.35, respectively (secukinumab IV!150 mg), 0.22
and 0.20, respectively (secukinumab IV!75 mg), and
0.70 and 0.46, respectively (placebo!secukinumab).
Thus, although placebo! secukinumab data showed a
higher progression rate using linear extrapolation of miss-
ing values, both data sets were comparable for both secu-
Figure 2. Cumulative probability plots of mean changes in the modified total Sharp/van der Heijde score (SHS; mTSS). Top, Mean changes
from baseline to week 24 in patients receiving intravenous (IV) secukinumab followed by subcutaneous secukinumab at a dose of 150 mg
(IV!150 mg) or 75 mg (IV!75 mg) and placebo-treated patients. Data are for the full analysis set, with linear extrapolation for all patients
who underwent radiographic assessment at week 16. Bottom, Mean changes from week 24 to week 52 in patients receiving secukinumab. Data
are for radiography completers (patients who had radiographic assessments at baseline, week 16 or 24, and week 52), with no extrapolation
applied.
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kinumab groups, indicating that the radiography complet-
er analysis offered a conservative estimate.
Structural progression from week 24 to week 52
in anti-TNF–naive patients receiving secukinumab
remained low (Table 1). The mean changes in the modi-
fied total SHS in the secukinumab 150 mg and 75 mg
groups were 20.01 and 0.14, respectively. Among
patients with an inadequate response or intolerance to
anti-TNF, the mean changes in the modified total SHS
were 0.91 in the secukinumab 150 mg group and 0.34 in
the secukinumab 75 mg group. Among patients who
switched from placebo to secukinumab at week 24, low
progression was observed in both the anti-TNF–naive
subgroup and the subgroup of patients with an inade-
quate response or intolerance to anti-TNF treatment.
The mean changes in the modified total SHS from week
24 to week 52 in anti-TNF–naive patients and those with
an inadequate response to anti-TNF treatment in the
placebo!secukinumab arm were 20.12 and 0.27, res-
pectively. Furthermore, low radiographic progression
was observed in the exploratory analysis in patients with
and those without concomitant MTX therapy (Table 1).
An exposure-response analysis showed a similar
relationship between the secukinumab IV!SC and the
placebo!secukinumab treatment groups at week 52 (see
Supplementary Figure 2a, available on the Arthritis &
Rheumatology web site at http://onlinelibrary.wiley.com/
doi/10.1002/art.39685/abstract). This suggested that the
IV!SC and SC regimens have a comparable effect on
radiographic progression, and that IV loading is not criti-
cal to prevent structural progression. Trends in sub-
groups stratified according to TNF inhibitor status were
also apparent in this analysis. Patients who had an inade-
quate response to anti-TNF treatment and low sec-
ukinumab concentrations were at particular risk of a
higher rate of radiographic progression (see Supplemen-
tary Figure 2b). All 5 patients with the greatest increase
in the modified total SHS were in the subgroup with an
inadequate response to anti-TNF treatment and had low
(Cmin#10 mg/ml) drug concentrations.
Inhibition of structural progression. Data on
radiography completers (no extrapolation applied) from
the overall population demonstrated a sustained thera-
peutic effect (modified total SHS change from baseline
of #0.5) of secukinumab on radiographic assessment
from baseline to week 24 and from week 24 to week 52.
In the secukinumab IV!150 mg group, 82.3% and
85.7% of patients had inhibition of structural progres-
sion from baseline to week 24 and from week 24 to week
52, respectively. In the secukinumab IV!75 mg group,
92.3% and 85.8% had inhibition of progression from
baseline to week 24 and from week 24 to week 52,
respectively. The proportion of placebo-treated patients
with inhibition of structural progression significantly
increased from 75.7% (baseline to week 24) to 86.8%
(week 24 to week 52) following secukinumab treatment
(P5 0.0131). The switch from placebo to secukinumab
at week 24 reduced the structural progression rate from
24.3% to 13.2%. Eleven of the 12 patients who had a
high rate of progression (all with a modified total SHS of
.3) had low (Cmin #15 mg/ml) secukinumab concentra-
tions at week 52.
DISCUSSION
The results of the current study demonstrate that
secukinumab inhibited radiographic disease progression
in the overall PsA patient population, and that this inhi-
bition was sustained for up to 52 weeks. Inhibition was
observed for both erosion and JSN scores. Furthermore,
progression in placebo-treated patients was inhibited by
switching to secukinumab treatment. In patients who
showed the highest levels of radiographic progression,
suboptimal secukinumab concentrations may have been
linked to an increased likelihood of progression.
Subgroup analyses showed radiographic benefits
of secukinumab up to week 24, regardless of prior anti-
TNF exposure. From week 24 to week 52, a low rate of
radiographic progression was observed in secukinumab-
treated patients in the anti-TNF–naive subgroup but not
in secukinumab-treated patients in the subgroup with
an inadequate response to anti-TNF treatment.
Although these data should be interpreted with caution
due to small patient numbers, this difference may be
attributable to the difficulties associated with treatment
in this latter population. The exploratory exposure-
response analysis indicated that insufficient secukinu-
mab exposure after the IV loading period may have pre-
vented adequate inhibition of radiographic progression
in the subgroup with an inadequate response to anti-
TNF treatment, although there was no tendency toward
a lower rate of progression in the higher-dose secuki-
numab group during the loading period. Thus,
patients with an inadequate response or intolerance to
anti-TNF therapy may require a higher dose of secuki-
numab to maintain acceptable secukinumab exposure
levels for inhibition of structural damage.
Inhibition of structural damage was demonstrated
through week 52, regardless of whether patients were
receiving concomitant MTX, although these data should
be interpreted with caution due to the fact that patients
had active disease despite receiving MTX. The effect of
concomitant MTX can be assessed only in an active com-
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parator trial with both MTX-naive patients and those
who have been treated with MTX.
Compared with placebo, secukinumab signifi-
cantly reduced radiographic progression, demonstrating
a disease-modifying effect. The average progression rate
in all groups was low, although a small proportion of
patients, especially those in the placebo groups, showed
significant progression. Clinical trials are not appropri-
ate for assessing the clinical relevance of this reduction;
instead, this needs to be determined using long-term
observational cohorts. Also, it should be noted that the
mean modified total SHS may not adequately reflect
radiographic progression and should be interpreted with
care, because it may be disproportionately influenced by
outliers.
In FUTURE 1, the efficacy of secukinumab for
inhibiting radiographic disease progression and improving
clinical measures was comparable between the IV!
150 mg and IV!75 mg dose arms after 24 weeks, due to
the IV loading dose resulting in similar levels of expo-
sure across both arms (7). In the recently published
FUTURE 2 trial, which used subcutaneous loading and
maintenance dosing but did not include a radiographic
outcome measure, secukinumab 300 mg and 150 mg sig-
nificantly improved a range of clinical outcomes in
patients with PsA compared with placebo at week 24,
while secukinumab 75 mg was ineffective (10). Conse-
quently, the 150 mg and 300 mg secukinumab doses
were recently approved for PsA in Europe.
A recent systematic review highlighted the inhibi-
tory effect of anti-TNF agents on structural damage in
PsA (11). However, failure of anti-TNF treatment, loss of
efficacy, and intolerance in some patients highlight the
unmet need for new therapies with an alternative mecha-
nism of action (12). The radiographic findings from this
study are consistent with those from other trials of TNF
and IL-12/23 inhibitors involving anti-TNF–naive popula-
tions (13–17) and suggest that IL-17A may offer an addi-
tional therapeutic option for patients with PsA.
The current study has several limitations. First,
patients who were nonresponders at week 16 were not
assessed at week 24, and radiographic data on these
patients were estimated by linear extrapolation. Addi-
tionally, only erosions and JSN were assessed, and no
information on bone formation was provided. However,
this is a theoretical consideration, because a previous
trial suggested that new bone development may not
occur during the typical treatment period of 1 year (17).
Of note, tender and swollen joint counts were chosen for
this trial because these are commonly used in phase III
studies of PsA. Newer measures such as the Simplified
Disease Activity Index (18) and the Clinical Disease
Activity Index (19) have not been used in this setting to
date and therefore were not considered appropriate.
In conclusion, in the present study secukinumab
treatment was associated with sustained inhibition of
radiographic progression in patients with active PsA.
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